This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 May;7(5):375-6.

doi: 10.1016/S1474-4422(08)70066-8. Epub 2008 Apr 2.

Towards gene therapy for Parkinson's disease

Stéphane Palfi

PMID: 18387851
DOI: 10.1016/S1474-4422(08)70066-8

Comment

Towards gene therapy for Parkinson's disease

Stéphane Palfi. Lancet Neurol. 2008 May.

. 2008 May;7(5):375-6.

doi: 10.1016/S1474-4422(08)70066-8. Epub 2008 Apr 2.

Author

Stéphane Palfi

PMID: 18387851
DOI: 10.1016/S1474-4422(08)70066-8

No abstract available

PubMed Disclaimer

Comment on

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT. Marks WJ Jr, et al. Lancet Neurol. 2008 May;7(5):400-8. doi: 10.1016/S1474-4422(08)70065-6. Epub 2008 Apr 2. Lancet Neurol. 2008. PMID: 18387850 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information